Invesco Ltd. Fate Therapeutics Inc Transaction History

Invesco Ltd.

$503 Billion
Q1 2025

A detailed history of Invesco Ltd. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Invesco Ltd. holds 213,503 shares of FATE stock, worth $222,043. This represents 0.0% of its overall portfolio holdings.

Number of Shares

213,503

Previous 108,934 95.99%

Holding current value

$222,043

Previous $179,000 6.15%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$0.79 - $1.87 $82,609 - $195,544	104,569 Added 95.99%	213,503 $168,000
Q4 2024 Feb 13, 2025	BUY	$1.61 - $3.35 $11,360 - $23,637	7,056 Added 6.93%	108,934 $179,000
Q3 2024 Nov 12, 2024	SELL	$3.12 - $5.57 $680 - $1,214	-218 Reduced 0.21%	101,878 $356,000
Q2 2024 Aug 13, 2024	SELL	$3.26 - $7.08 $2.81 Million - $6.11 Million	-863,335 Reduced 89.42%	102,096 $334,000
Q1 2024 May 14, 2024	BUY	$3.54 - $8.35 $2.96 Million - $6.98 Million	835,977 Added 645.77%	965,431 $7.09 Million
Q4 2023 Feb 12, 2024	BUY	$1.65 - $3.94 $6,380 - $15,235	3,867 Added 3.08%	129,454 $484,000
Q3 2023 Nov 13, 2023	BUY	$2.02 - $5.04 $13,717 - $34,226	6,791 Added 5.72%	125,587 $266,000
Q2 2023 Aug 11, 2023	SELL	$4.76 - $6.59 $21,253 - $29,424	-4,465 Reduced 3.62%	118,796 $565,000
Q1 2023 May 12, 2023	BUY	$4.24 - $11.12 $321,315 - $842,695	75,782 Added 159.61%	123,261 $702,000
Q4 2022 Feb 13, 2023	SELL	$9.86 - $23.83 $36,353 - $87,861	-3,687 Reduced 7.21%	47,479 $479,000
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $76,080 - $130,392	3,616 Added 7.6%	51,166 $1.15 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $17.2 Million - $41 Million	-967,567 Reduced 95.32%	47,550 $1.18 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $3.91 Million - $7.95 Million	131,838 Added 14.93%	1,015,117 $39.4 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $36.5 Million - $49.1 Million	762,832 Added 633.33%	883,279 $51.7 Million
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $45.3 Million - $73.1 Million	-763,687 Reduced 86.38%	120,447 $7.14 Million
Q2 2021 Aug 17, 2021	BUY	$67.25 - $92.52 $13.9 Million - $19.2 Million	206,998 Added 30.57%	884,134 $76.7 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $18.3 Million - $29.7 Million	253,280 Added 59.76%	677,136 $55.8 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $3.9 Million - $10.3 Million	102,309 Added 31.82%	423,856 $38.5 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $9.02 Million - $12 Million	296,773 Added 1197.92%	321,547 $12.9 Million
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $2.48 Million - $4.32 Million	-122,688 Reduced 83.2%	24,774 $850,000
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $2.55 Million - $4.7 Million	147,462 New	147,462 $3.28 Million
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $775,155 - $1.13 Million	-50,107 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $47,953 - $62,791	-3,072 Reduced 5.78%	50,107 $1.02 Million
Q1 2019 May 15, 2019	SELL	$13.15 - $18.71 $232,531 - $330,848	-17,683 Reduced 24.95%	53,179 $934,000
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $813,495 - $1.2 Million	70,862 New	70,862 $909,000

Others Institutions Holding FATE

# of Institutions

144

Shares Held

97M

Call Options Held

56.7K

Put Options Held

5.4K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $101M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account